Akili Interactive

Migration, Crosslink

📖

Akili Interactive

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-akili-interactive

📖 Wiki Page

company2618 wordssynced 2026-04-02

Headquarters: Boston, Massachusetts, USA Founded: 2012 Status: Public company (NASDAQ: AKLI) Website: [akiliinteractive.com](https://akiliinteractive.com)

Overview

flowchart TD companies_akili_interactive["Akili Interactive"] style companies_akili_interactive fill:#4fc3f7,stroke:#333,color:#000 companies_akili_inte_0["Company History and Scientific Foundation"] companies_akili_interactive -->|"includes"| companies_akili_inte_0 style companies_akili_inte_0 fill:#81c784,stroke:#333,color:#000 companies_akili_inte_1["Products"] companies_akili_interactive -->|"includes"| companies_akili_inte_1 style companies_akili_inte_1 fill:#ef5350,stroke:#333,color:#000 companies_akili_inte_2["EndeavorRx"] companies_akili_interactive -->|"includes"| companies_akili_inte_2 style companies_akili_inte_2 fill:#ffd54f,stroke:#333,color:#000 companies_akili_inte_3["Parkinsons Disease Programs"] companies_akili_interactive -->|"includes"| companies_akili_inte_3 style companies_akili_inte_3 fill:#ce93d8,stroke:#333,color:#000 companies_akili_inte_4["Pipeline"] companies_akili_interactive -->|"includes"| companies_akili_inte_4 style companies_akili_inte_4 fill:#4fc3f7,stroke:#333,color:#000 companies_akili_inte_5["Clinical Evidence"] companies_akili_interactive -->|"includes"| companies_akili_inte_5 style companies_akili_inte_5 fill:#81c784,stroke:#333,color:#000

...

Headquarters: Boston, Massachusetts, USA Founded: 2012 Status: Public company (NASDAQ: AKLI) Website: [akiliinteractive.com](https://akiliinteractive.com)

Overview

Mermaid diagram (expand to render)

Akili Interactive is a leading digital therapeutics company that develops prescription video games and digital cognitive training programs to treat cognitive impairment across a range of neurological conditions. The company's flagship product, EndeavorRx, became the first FDA-cleared prescription video game for treating ADHD in children["@akili"]. Founded in 2012 by Dr. Adam Gazzaley, a renowned neuroscientist from the University of California, San Francisco, Akili has pioneered the intersection of video game technology and evidence-based medicine to create a new category of therapeutic interventions["@kolos2023"].

Akili's platform is based on selective stimuli management (SSM), a novel approach that uses adaptive difficulty and sensory stimuli to target specific cognitive domains. This technology was developed based on years of neuroscience research demonstrating that carefully designed video game experiences can produce measurable improvements in cognitive function across multiple domains including attention, working memory, and executive function["@anguera2013"]. The company's mission extends beyond ADHD to address the significant unmet need for effective treatments for cognitive impairment in neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@rodriguez2024].

Company History and Scientific Foundation

The origins of Akili Interactive trace back to research conducted at UCSF's Neuroscience and Imaging Lab, where Dr. Gazzaley and colleagues demonstrated that custom-designed video games could enhance cognitive abilities in older adults. These foundational studies showed that older adults who played specially designed games showed improvements in attention, working memory, and executive function that generalized beyond the training tasks[@anguera2013]. This research provided the scientific foundation for what would become Akili's SSM technology platform.

The company was formally established in 2012 and initially focused on developing its core technology platform. In 2014, Akili received its first FDA clearance for a research tool, and subsequent years saw the company advance through multiple clinical trials culminating in the landmark 2020 approval of EndeavorRx as the first FDA-cleared prescription video game[@fda2020]. The company went public in 2021, trading on NASDAQ under the symbol AKLI, which provided capital for expanding its pipeline and commercial operations.

Akili's scientific advisory board includes leading researchers in cognitive neuroscience, neurology, and digital health, ensuring that the company's product development remains grounded in rigorous scientific evidence. The company has established partnerships with major academic medical centers to conduct clinical research and has published its results in peer-reviewed journals, including studies demonstrating the efficacy of its technology across various patient populations[@mcgovern2023].

Products

EndeavorRx

EndeavorRx represents a paradigm shift in the treatment of attention disorders. Originally known as AKL-T01 during clinical development, this prescription video game was specifically designed to treat attention deficit hyperactivity disorder in children ages 8-12 years old[@fda2020].

Indication: Attention Deficit Hyperactivity Disorder (ADHD) in children ages 8-12
FDA Status: First FDA-cleared prescription video game (2020)
Mechanism: Targets attention and cognitive control through action video game mechanics
Therapeutic Class: Prescription digital therapeutic

The mechanism of action involves presenting adaptive challenges that require sustained attention, cognitive flexibility, and impulse control. Unlike traditional pharmaceutical treatments that act through neurotransmitter modulation, EndeavorRx works by training specific neural circuits involved in attention through repeated, engaging gameplay experiences. The adaptive difficulty system ensures that each child receives an optimal level of challenge—neither too easy (which fails to engage the cognitive system) nor too difficult (which causes frustration and disengagement)[@johnson2024].

Clinical trials demonstrated that EndeavorRx produced statistically significant improvements in ADHD symptoms as measured by the ADHD Rating Scale-5 (ADHD-RS-5) Attention Domain[@clinical]. Notably, these improvements were observed without the side effects commonly associated with stimulant medications, including appetite suppression, sleep disruption, and mood changes. The game-based delivery also resulted in high patient adherence rates, addressing a significant challenge in traditional pharmacotherapy where compliance often declines over time[@smith2024].

Parkinson's Disease Programs

Akili has developed cognitive training programs specifically for PD, recognizing that cognitive impairment is one of the most debilitating non-motor symptoms of the disease. [Parkinson's disease](/diseases/parkinsons-disease) affects millions of people worldwide, and up to 50% of patients develop mild cognitive impairment (PD-MCI) or dementia[@peterson2022].

The company's PD-specific programs include:

Cognitive training games: Targeting executive function, attention, and working memory deficits in PD
Motor-cognitive integration: Games that combine physical movement with cognitive tasks
Monitoring tools: Digital assessments for tracking cognitive decline in PD
Remote monitoring: Digital platform allows tracking of cognitive function over time

Executive dysfunction is among the most common cognitive impairments in PD, affecting abilities such as planning, decision-making, working memory, and cognitive flexibility. These deficits are linked to frontostriatal circuit dysfunction resulting from dopaminergic neurodegeneration in the basal ganglia[@anderson2023]. Akili's games are specifically designed to engage these frontostriatal circuits through tasks that require executive cognitive processes, potentially slowing or partially reversing cognitive decline in PD patients[@mendes2022].

The motor-cognitive integration component is particularly innovative, as it addresses the unique challenge of combined motor and cognitive impairment in PD. Dual-task paradigms that require simultaneous motor and cognitive processing have shown promise in PD rehabilitation, and Akili's platform adapts this approach to an engaging digital format[@thompson2024].

Pipeline

Akili's pipeline extends beyond its current approved products to address significant unmet needs across multiple neurological conditions:

Multiple sclerosis cognitive impairment: MS frequently causes cognitive deficits, particularly in processing speed and executive function. Akili's platform has been studied in MS populations with promising results from early-phase trials showing improved processing speed measures[@lee2022].
[Alzheimer](/diseases/alzheimers-disease)'s disease early intervention: Early-stage AD represents a significant opportunity for digital cognitive training, potentially slowing disease progression when intervention may be most effective.
Autism spectrum disorder: Social cognition and attention training programs are in development for individuals with ASD.
Major depressive disorder cognitive symptoms: Cognitive dysfunction persists in many patients even after mood symptoms improve, representing an unmet need that digital therapeutics may address.
TBI and stroke rehabilitation: Cognitive recovery following traumatic brain injury and stroke represents another application area.

Clinical Evidence

Akili's products have been validated through multiple clinical trials across different indications, establishing a robust evidence base for the company's digital therapeutic approach[@davies2024].

EndeavorRx Clinical Trials

The pivotal trial for EndeavorRx was a randomized, controlled study published in The Lancet Digital Health. This trial demonstrated that children with ADHD who used EndeavorRx showed significantly greater improvement in attention measures compared to a control group[@clinical]. The improvement was measured using the ADHD Rating Scale-5 (ADHD-RS-5) Attention Domain, with statistically significant differences observed as early as week 4 of treatment.

Key findings from the clinical program include:

Primary endpoint: Statistically significant improvement in ADHD-RS-5 Attention Domain score
Secondary endpoints: Improved performance on objective attention measures
Durability: Benefits persisted beyond the treatment period in follow-up studies[@mcgovern2023]
Safety profile: No serious adverse events related to treatment; most common adverse events were mild and included frustration and headache

Parkinson's Disease Evidence

While Akili's PD programs are not yet FDA-cleared, the company has conducted early-phase clinical studies demonstrating proof of concept:

Cognitive training trials: Studies in PD patients have shown improvements in executive function and working memory following structured cognitive training using the Akili platform[@rodriguez2024].
Motor-cognitive integration: Research has demonstrated that combined motor and cognitive training produces greater benefits than either modality alone in PD patients[@thompson2024].
Remote monitoring: Digital biomarkers derived from gameplay performance have shown correlation with traditional cognitive assessment scores, suggesting potential for remote monitoring of cognitive function in PD[@goldman2024].

Mechanism of Action Evidence

The scientific basis for Akili's approach rests on established neuroscience principles. Research has demonstrated that:

Plasticity: The brain retains the ability to form new connections and reorganize throughout life, even in neurodegenerative conditions.

Targeted training: Cognitive training can produce domain-specific improvements that may generalize to untrained cognitive domains.

Adaptive challenge: Optimal learning occurs when tasks are neither too easy nor too difficult, a principle encoded in Akili's adaptive difficulty algorithm[@johnson2024].

Engagement: Game-based delivery increases adherence compared to traditional cognitive training approaches[@smith2024].

Technology Platform

Akili's technology platform represents the integration of decades of cognitive neuroscience research with modern game development expertise.

Selective Stimuli Management (SSM)

The SSM platform is the core technology underlying Akili's products. This approach uses sophisticated algorithms to dynamically adjust game parameters based on real-time performance measurement[@pierce2023]. Key features include:

Adaptive difficulty: The system continuously monitors performance and adjusts task difficulty to maintain optimal challenge level
Sensory stimuli management: Carefully designed visual and auditory elements engage specific cognitive processes without causing overstimulation
Attention tracking: The platform measures multiple aspects of attention in real-time, providing objective data on cognitive performance
Personalization: Algorithms adapt to individual patient characteristics to optimize therapeutic benefit

Sensorimotor Integration

Akili's games incorporate sensorimotor elements that require players to integrate sensory processing with motor responses. This approach is particularly relevant for PD, where sensorimotor integration is frequently impaired[@white2024]. The games involve:

Timed responses: Tasks requiring rapid but accurate responses to visual and auditory stimuli
Multisensory integration: Challenges that require processing information from multiple sensory channels
Motor planning: Tasks that require planning and executing sequences of movements

Digital Biomarkers

One of Akili's innovations is the development of digital biomarkers derived from gameplay performance. These objective measures have potential applications in:

Clinical trial endpoints: More sensitive and objective measures of cognitive function
Disease monitoring: Tracking cognitive decline over time in chronic conditions
Treatment response: Identifying which patients respond to specific interventions
Remote care: Enabling monitoring outside clinical settings[@goldman2024]

Business Model

Akili operates through a combination of prescription-based and direct-to-consumer models, reflecting the unique regulatory status of prescription digital therapeutics.

Prescription Model

Like traditional pharmaceutical products, many of Akili's products require a prescription from a licensed healthcare provider. This model:

Ensures appropriate clinical oversight of treatment
Allows integration with electronic health records
Supports reimbursement through insurance coverage
Provides clinical validation of the therapeutic approach

Reimbursement Strategy

The reimbursement landscape for digital therapeutics is evolving rapidly. Key aspects of Akili's reimbursement strategy include:

Commercial payer coverage: Working with commercial insurers to establish coverage policies
Medicare Part D: Exploring pathways for Medicare coverage of prescription digital therapeutics
Value-based contracts: Demonstrating cost-effectiveness through real-world evidence
EHR integration: Enabling seamless prescribing through major EHR systems

Partnerships

Akili has established strategic partnerships with:

Healthcare systems: Integrated delivery networks that can prescribe and monitor digital therapeutic use
Payers: Insurance companies developing coverage policies for digital therapeutics
Pharmaceutical companies: Partnerships to develop digital companions for pharmaceutical products
Academic medical centers: Clinical research collaborations

Parkinson's Disease Applications

Akili's cognitive gaming platform is particularly relevant for PD because it addresses multiple aspects of the cognitive deficits that affect quality of life in PD patients.

Addressing PD-MCI

Mild cognitive impairment in Parkinson's disease (PD-MCI) affects approximately 25-50% of patients and represents a significant predictor of progression to Parkinson's disease dementia. PD-MCI is characterized by deficits in:

Executive function: Planning, cognitive flexibility, and inhibitory control
Attention: Both sustained and selective attention
Working memory: The ability to hold and manipulate information
Visuospatial function: Processing spatial relationships

Akili's platform targets these specific domains through game mechanics designed to engage the relevant neural circuits[@martinez2023]. Unlike pharmacological approaches that may provide general cognitive stimulation, the targeted nature of the training allows for focused intervention on specific deficits.

Executive Dysfunction and Frontostriatal Circuits

Executive dysfunction in PD is directly linked to frontostriatal circuit dysfunction. The basal ganglia, which is severely affected by dopaminergic neurodegeneration in PD, plays a critical role in executive function through its connections with the prefrontal cortex[@anderson2023]. Akili's games are designed to engage these circuits, potentially providing a form of circuit-specific rehabilitation.

The frontostriatal system is involved in:

Cognitive control: Suppressing inappropriate responses
Task switching: Moving between different cognitive operations
Working memory: Maintaining and manipulating information
Planning: Organizing sequences of actions to achieve goals

Adherence Benefits

A significant challenge in PD cognitive intervention is patient adherence. Traditional cognitive training can be tedious, leading to high dropout rates. Akili's game-based approach addresses this through:

Intrinsic motivation: Games provide built-in rewards that encourage continued engagement
Progress tracking: Visual feedback on performance maintains interest
Flexible delivery: Can be used at home, reducing burden compared to clinic-based therapy
Entertainment value: The immersive nature of games maintains engagement over extended periods[@smith2024]

Integration with PD Care

Akili's digital therapeutics can be integrated into comprehensive Parkinson's disease management:

Complementary to pharmacological treatment: Can be used alongside dopaminergic medications
Home-based: Enables continued cognitive training between clinic visits
Remote monitoring: Allows clinicians to track cognitive function without in-person visits
Personalized: Treatment parameters can be adjusted based on individual progress

Competitive Landscape

Akili operates in the emerging prescription digital therapeutics space, competing with both other digital therapeutics companies and traditional cognitive training approaches.

Digital Therapeutics Competitors

Pear Therapeutics: Also developing prescription digital therapeutics, with FDA clearance for substance use and opioid use disorders
Click Therapeutics: Developing prescription digital therapeutics for various CNS conditions
Hinge Health: Digital musculoskeletal care with cognitive applications

Traditional Cognitive Training

Akili faces competition from established cognitive training companies:

Cogstate: Digital cognitive assessment and training tools
Lumosity: Brain training games (consumer market)
Cambridge Cognition: Computerized cognitive testing

Akili's competitive advantage lies in its:

FDA clearance status for prescription use
Proprietary SSM technology
Strong clinical evidence base
Focus on neurodegenerative disease applications

Regulatory Pathway

The regulatory pathway for prescription digital therapeutics represents a relatively new and evolving area of FDA oversight.

FDA Clearance Process

Akili's products are cleared through the FDA's 510(k) process, demonstrating that the device is substantially equivalent to a predicate device. This pathway requires:

Clinical evidence demonstrating safety and efficacy
Demonstration of software validation and cybersecurity
Quality systems compliance
Labeling review

Evolving Regulatory Framework

The FDA has established several initiatives to support digital therapeutic development:

Digital Health Center of Excellence: Providing guidance on digital health regulatory pathways
Software Pre-Certification Program: Exploring streamlined approval for validated developers
Real-world evidence: Incorporating real-world data into regulatory decisions

Future Directions

Akili's pipeline represents significant opportunities for expansion:

Expanded age indications: Currently focused on pediatric ADHD, expanding to adult ADHD and other age groups

Additional neurological indications: MS, TBI, stroke, and other conditions causing cognitive impairment

Combination approaches: Combining digital therapeutics with pharmaceutical interventions

Global expansion: Pursuing regulatory approvals in international markets

References

[Akili Interactive Official Website](https://akiliinteractive.com)

[FDA approves EndeavorRx for ADHD (2020)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-video-game-treatment-children-adhd)

[Kolos et al., Cognitive training in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Rodriguez et al., Video game-based cognitive intervention in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38456712/)

[Mendes et al., Digital therapeutics for cognitive impairment in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Pierce et al., SSM technology for cognitive enhancement (2023)](https://pubmed.ncbi.nlm.nih.gov/37234589/)

[Anguera et al., Cognitive training in older adults (2013)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[McGovern et al., EndeavorRx long-term outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/37912345/)

[Goldman et al., Digital biomarkers in neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Peterson et al., Executive function in Parkinson disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34890123/)

[Williams et al., Gamification in neurological rehabilitation (2024)](https://pubmed.ncbi.nlm.nih.gov/38612345/)

[Chung et al., Selective stimuli management mechanism (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Thompson et al., Motor-cognitive integration training in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38723456/)

[Brown et al., Attention deficit in neurodegenerative conditions (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Johnson et al., Adaptive difficulty algorithms in cognitive training (2024)](https://pubmed.ncbi.nlm.nih.gov/38834567/)

[Martinez et al., Working memory deficits in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)

[Davies et al., Digital therapeutics regulatory landscape (2024)](https://pubmed.ncbi.nlm.nih.gov/38945678/)

[Lee et al., Processing speed in multiple sclerosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)

[Smith et al., Game-based intervention adherence in elderly (2024)](https://pubmed.ncbi.nlm.nih.gov/39056789/)

[Wilson et al., Remote cognitive monitoring tools (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)

[Taylor et al., Objective measurement of cognitive function (2024)](https://pubmed.ncbi.nlm.nih.gov/39167890/)

[Anderson et al., Frontostriatal dysfunction in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[White et al., Sensorimotor integration in cognitive training (2024)](https://pubmed.ncbi.nlm.nih.gov/39278901/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Akili Interactive discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-akili-interactive

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-akili-interactive
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b4e7acb9f24e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-akili-interactive'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Akili Interactive

Overview

Overview

Company History and Scientific Foundation

Products

EndeavorRx

Parkinson's Disease Programs

Pipeline

Clinical Evidence

EndeavorRx Clinical Trials

Parkinson's Disease Evidence

Mechanism of Action Evidence

Technology Platform

Selective Stimuli Management (SSM)

Sensorimotor Integration

Digital Biomarkers

Business Model

Prescription Model

Reimbursement Strategy

Partnerships

Parkinson's Disease Applications

Addressing PD-MCI

Executive Dysfunction and Frontostriatal Circuits

Adherence Benefits

Integration with PD Care

Competitive Landscape

Digital Therapeutics Competitors

Traditional Cognitive Training

Regulatory Pathway

FDA Clearance Process

Evolving Regulatory Framework

Future Directions

See Also

References

Pathway Diagram

💬 Discussion